



Tiglutik™ (riluzole) Oral Suspension
Effective 04/01/19

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Tiglutik are indicated for the treatment of amyotrophic lateral sclerosis (ALS)

Coverage Guidelines

Authorization may be reviewed for members new to AllWays Health Partners who are currently receiving treatment with Tiglutik excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. Member is diagnosed with amyotrophic lateral sclerosis (ALS)
2. Member is at least 18 years of age
3. Member has documented inability to swallow oral riluzole tablets

Limitations

1. Initial and reauthorizations will be granted for 24 months.

References

1. Tiglutik (riluzole) [prescribing information]. Berwyn, PA: ITF Pharma Inc; September 2018.
2. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012; CD001447.
3. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330:585.
4. Kennel P, Revah F, Bohme GA, et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pnm). J Neurol Sci 2000; 180:55.

**Review History**

02/20/19 – Reviewed

07/21/2021 – Reviewed July P&T; separated Comm/Exch vs. MH; update document to include started and stabilized statement,

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.